American Society of Hirudotherapy

Post-Herpetic Neuralgia (Investigational Adjunct)

Investigational adjunct for chronic post-herpetic neuralgia; gabapentinoids, tricyclics, and topical lidocaine/capsaicin remain evidence-based; herpes zoster vaccine prevents new cases.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for post-herpetic neuralgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
What evidence exists?
Tier C (investigational). No controlled trial of leech therapy for post-herpetic neuralgia was found in the medical literature searched; the human reports found are isolated case reports, and a registered pilot study was terminated early after 6 patients. Evidence-based first-line therapies with strong RCT support are: gabapentin or pregabalin, tricyclic antidepressants (nortriptyline, amitriptyline), duloxetine, topical lidocaine 5 percent patch, topical capsaicin 8 percent patch, and (for refractory cases) opioids or interventional pain procedures. Prevention with the recombinant shingles vaccine (Shingrix) is highly effective. Most post-herpetic neuralgia improves over months to a year, but a minority have persistent pain that profoundly affects quality of life.
Main risks
  • Bleeding from the bite site for 6 to 24 hours after detachment
  • Bruising over previously herpes-affected skin for 5 to 10 days
  • REACTIVATION RISK: trauma to dermatome may trigger zoster recurrence or transient symptom flare
  • Local skin or, rarely, Aeromonas hydrophila infection
  • Allergic reaction to leech saliva (uncommon)
  • Worsening of allodynia and burning pain from local irritation
  • Delay of evidence-based pharmacotherapy and interventional pain procedures
  • Risk in elderly or frail patients with anemia or fall risk
Who should not consider this
  • Patients with active herpes zoster lesions (vesicles, crusting) - this is a contagious viral infection
  • Patients with disseminated zoster or zoster ophthalmicus involving V1 distribution
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Immunocompromised patients (chemotherapy, HIV, transplant, high-dose corticosteroids)
  • Patients who have not tried evidence-based pharmacotherapy (gabapentinoids, TCAs, topical agents)
  • Patients with active dermatitis or broken skin over the affected dermatome
What to ask your clinician
  • Have I tried gabapentin or pregabalin at adequate doses and duration?
  • Have I tried tricyclic antidepressants (nortriptyline) or duloxetine?
  • Have I tried topical 5 percent lidocaine or 8 percent capsaicin patch?
  • Am I a candidate for interventional pain procedures (nerve block, intercostal block, sympathetic block, spinal cord stimulator)?
  • Have I received the recombinant shingles vaccine (Shingrix) to prevent recurrence?
  • Where exactly will the leech be placed - confirm NEVER over active or recently healed zoster lesions?
  • What is the practitioner's plan if symptoms worsen or if zoster reactivates?
When to seek urgent care
  • New crops of vesicles or spreading rash (possible zoster reactivation or dissemination)
  • Eye pain, visual change, or rash on the forehead or nose (possible zoster ophthalmicus - sight-threatening)
  • Fever, chills, or systemic symptoms with the rash (possible disseminated zoster)
  • Severe worsening of pain, numbness, or new weakness in the affected dermatome
  • Bleeding from a bite site lasting more than 24 hours
  • Spreading redness, pus, or warmth at the bite site
  • Hives, facial or throat swelling, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for post-herpetic neuralgia.
  • It does not replace gabapentinoids, TCAs, duloxetine, or topical lidocaine and capsaicin patches - all with RCT support.
  • It does not prevent zoster recurrence; only Shingrix vaccination does.
  • Trauma to a previously herpes-affected dermatome may trigger a flare rather than relieve pain.
  • It is never applied to active herpes zoster lesions, which are viral and contagious.

Clinical Profile

Category
Neurological
ICD-10
B02.22, B02.29, G53.0
Safety tier
Medium

Evidence Summary

Post-herpetic neuralgia (PHN) is neuropathic pain persisting beyond 90 days after herpes zoster. Evidence-based pharmacotherapy includes gabapentin or pregabalin, tricyclic antidepressants, topical lidocaine 5 percent patch, and topical capsaicin 8 percent (one-time clinic application). Opioids have a limited role given chronic risks. Recombinant zoster vaccine (Shingrix) substantially prevents shingles and PHN in adults 50 and older. No controlled trial or case series of hirudotherapy for post-herpetic neuralgia was identified in PubMed, Europe PMC or ClinicalTrials.gov. The human evidence is limited to isolated case reports of leech therapy in herpes zoster: one patient with recurrent zoster and post-herpetic neuralgia treated with a multimodal regimen that included leeches (Schwickert and Saha 2006), and single patients with acute zoster (Nakanekar 2020; Itankar 2025). A pilot observational study of leech therapy for post-herpetic neuralgia (NCT01744522, University of Duisburg-Essen) was terminated after 6 of 20 planned patients, with no results posted and no publication identified. Any use is investigational. Application during active zoster would be inappropriate due to bleeding and contagion risks.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Postherpetic neuralgia is not described in the books: Baskova and Isakhanyan write neither about shingles nor about the pain that remains after it, and among the neuralgias they describe only neuralgia of the sciatic nerve and of the trigeminal nerve[B1].
  • Flecken and Michalsen likewise do not write about postherpetic neuralgia; the closest in their book is a short section on acute shingles (herpes zoster) in the chapter on indications, that is, about the disease itself and not about the pain that remains after it[B3].
  • According to Flecken and Michalsen, hirudotherapy has established itself as a viable alternative for the treatment of shingles, although no scientific data are available[B3].
  • They stress that treatment must be started in good time — no later than a week after the first symptoms appear, otherwise, in their words, the chances of success are poor; what to do about pain that persists later is not said in this section[B3].
  • The same authors write in the chapter on contraindications that, by experience, leech therapy during the acute stages of infectious diseases may lead to weakness and impaired wound healing; how this fits with their advice for shingles is not clear from the text[B3].
  • Baskova and Isakhanyan, as well as Flecken and Michalsen (chapter on contraindications), list hemophilia and concurrent use of anticoagulants among the contraindications[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Detailed Trial Entries

1 trial indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active herpes zoster (vesicles present or within 30 days)
  • Immunocompromised patient
  • Trigeminal-distribution PHN with facial placement plan (avoid face)
  • Suspected disseminated zoster

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.